Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
481-500 of 1,694 trials

Bipolar Depression: New Treatment Approach

We are investigating whether a six-week intensified medication plan helps people with bipolar depression who didn't respond to their first treatment. We’ll compare this new approach to standard care to see which is more effective.

Bipolar Depression≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Heart Health: Ticagrelor with Aspirin After CABG

We are studying whether adding ticagrelor to aspirin helps reduce heart-related events in patients after coronary artery bypass surgery. This trial also looks at the risk of bleeding and graft failure.

Coronary Artery Disease>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lennox-Gastaut Syndrome: Carisbamate Treatment Study

We are investigating whether carisbamate can help reduce drop seizures in children and adults with Lennox-Gastaut Syndrome. This study will also look at the safety and tolerability of the medication.

Lennox-Gastaut Syndrome3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Major Depressive Disorder: New Treatment Approach

We are studying whether a six-week intensified medication treatment helps people with major depressive disorder who didn't respond to their first treatment. The goal is to see if this new approach improves symptoms and overall well-being compared to standard care.

Major Depressive Disorder≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer: Lower Dose of CDK 4/6-Inhibitors

We are studying whether a lower initial dose of a cancer medication is effective for older breast cancer patients compared to the standard dose. This trial aims to improve treatment outcomes and quality of life for vulnerable patients.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyGynecology and ObstetricsOncology

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Ulcerative Colitis: Dual Therapy Study

We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.

Ulcerative Colitis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dapagliflozin for Heart Protection in Breast Cancer Patients

We are studying whether dapagliflozin can help prevent heart problems in breast cancer patients receiving chemotherapy. This trial compares its effects to a placebo over 12 months.

Secondary CardiomyopathyInvasive Breast Cancer3-6 monthsConfirmation phase (III)Standard MedicinesCardiologyOncology

Pulmonary Sarcoidosis: OATD-01 Treatment Study

We are studying the effects of OATD-01, an oral medication, on reducing lung inflammation in people with active pulmonary sarcoidosis. The trial will also look at safety, lung function, and quality of life.

Pulmonary Sarcoidosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

HER2-Positive Gastric Cancer: New Treatment Study

We are testing a new combination of medications for patients with HER2-positive gastric or gastroesophageal cancer. The goal is to see if it helps clear cancer markers and improves survival compared to standard chemotherapy.

Gastric or Gastroesophageal Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Idiopathic Hypersomnia: Melatonin and Light Therapy Study

We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.

Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rheumatoid Arthritis: New Biosimilar Drug Study

We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.

Rheumatoid Arthritis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Multiple Myeloma: Etentamig Treatment Study

We are studying a new medication, Etentamig, for adults with relapsed or refractory multiple myeloma who have already received multiple treatments. The goal is to see if it is more effective and safe compared to standard therapies.

Relapsed or Refractory Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Heart Failure: Colchicine and Thiamine Study

We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.

Heart Failure>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Localized Ocular Melanoma: IDE196 Treatment Study

We are testing the investigational drug IDE196 to see if it can shrink tumors in patients with localized ocular melanoma before surgery. The study aims to evaluate its safety and effectiveness in improving treatment outcomes.

Uveal MelanomaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOphthalmology

Metastatic Uveal Melanoma: IDE196 and Crizotinib Combination

We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.

Uveal Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Fertility Treatments: Comparing Ovarian Stimulation Methods

We are studying two ovarian stimulation methods to see which one improves quality of life and satisfaction for women seeking fertility preservation or genetic testing. This research aims to help tailor treatments based on individual needs.

Subfertility3-6 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesEndocrinologyGynecology and Obstetrics